These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Oral ganciclovir.
    Author: Schouten JT.
    Journal: STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979.
    Abstract:
    Oral ganciclovir (OG) has been approved by the Food and Drug Administration (FDA) for the prevention of primary and secondary cytomegalovirus (CMV) infection. OG (Cytovene) delays the appearance of CMV infection rather than preventing it. In a study comparing intravenous and oral ganciclovir, OG was found to be an effective treatment for the maintenance of CMV retinitis, while intravenous ganciclovir still needed to be used for new CMV infections. Syntex presented results from its study on the efficacy of OG as a primary prophylaxis for CMV infection. The study, using 725 people with positive CMV serology and CD4 counts below 100, was never completed because the group which received OG had a 49 percent decrease in the number of clinical CMV infections. A potential complication of OG use as a primary prophylaxis is ganciclovir resistance, and the oral form is more expensive than the intravenous form of the drug.
    [Abstract] [Full Text] [Related] [New Search]